MedPath

Trelagliptin

Generic Name
Trelagliptin
Drug Type
Small Molecule
Chemical Formula
C18H20FN5O2
CAS Number
865759-25-7
Unique Ingredient Identifier
Q836OWG55H

Overview

Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").

Indication

用于治疗2型糖尿病。

Associated Conditions

  • Glycemic Index

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes
2025/04/06
NCT06913101
Not Applicable
Active, not recruiting
PNS Hafeez - Naval Hospital
Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes
2025/03/21
NCT06889909
Not Applicable
Active, not recruiting
Lahore General Hospital
Dose Modification Requirement for Trelagliptin in Egyptian Population
2020/05/05
NCT04374864
Phase 4
UNKNOWN
British University In Egypt
Omarigliptin in Four Healthy Egyptian Volunteers
2020/04/28
NCT04365907
Not Applicable
UNKNOWN
British University In Egypt
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
2020/02/26
NCT04285983
N/A
Completed
Takeda
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
2019/05/07
NCT03940183
Phase 3
Completed
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
2018/06/13
NCT03555591
N/A
Completed
Takeda
Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers
2017/12/05
NCT03362398
Not Applicable
Completed
British University In Egypt
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
2017/07/27
NCT03231709
Phase 4
Completed
Takeda
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
2017/01/09
NCT03014479
Phase 4
Completed
Takeda

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Trelagliptin Succinate Tablets
四川科伦药业股份有限公司
国药准字H20223113
化学药品
片剂
3/8/2022
Trelagliptin Succinate Tablets
四川科伦药业股份有限公司
国药准字H20247112
化学药品
片剂
5/23/2024

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy